Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics reported a second-quarter profit and raised its full-year 2026 net product sales guidance. The company posted net income of $15.01 million, or $0.11 per share, compared with a loss of $15.89 million, or $0.13 per share, a year earlier. Total revenue rose to $129.86 million from $81.50 million, driven by higher demand for ZORYVE products and improved gross-to-net deductions. Arcutis now expects full-year net product sales of $525 million to $540 million, up from its prior forecast of $480 million to $495 million.

Arcutis Biotherapeutics President and CEO Todd Watanabe sold 4,375 shares on August 3, 2026, in a non-discretionary transaction to satisfy tax withholding obligations tied to the vesting of restricted stock units. The sale, valued at $114,275 based on a weighted average price of $26.12, left Watanabe with 950,337 total shares worth $24.65 million at the market close. The company reported second-quarter results on August 5, with roflumilast product Zoryve revenue growing 59% to $129.9 million and net income reaching $15 million, or $0.11 per share, compared to a net loss of $15.9 million a year earlier. Arcutis raised its full-year 2026 net product sales guidance to between $525 million and $540 million and received FDA approval to expand Zoryve's indication to treat plaque psoriasis in children as young as two.

Arcutis Biotherapeutics has appointed Christopher Peetz to its Board of Directors effective July 15, 2026. Peetz is co-founder and chief executive officer of Mirum Pharmaceuticals, a global organization focused on rare diseases, and brings extensive experience in guiding biopharmaceutical companies through expansion, product development, and strategic acquisitions. Arcutis president and CEO Frank Watanabe stated that Peetz's expertise will strengthen the board as the company executes its strategy to grow the ZORYVE franchise, expand into new indications, and build its pipeline. Board chairman Keith R. Leonard added that Peetz's proven leadership in building and scaling innovative organizations will be invaluable for Arcutis's next phase of growth. Peetz expressed honor in joining the board and looks forward to supporting the company's continued growth and success.

The U.S. FDA has accepted Arcutis Biotherapeutics' supplemental New Drug Application to expand the label of Zoryve 0.05% cream for infants aged 3 months to 24 months with mild-to-moderate atopic dermatitis. The treatment is already approved for children aged two to five years with the condition. If approved, Zoryve 0.05% would be the first once-daily advanced targeted topical treatment for this patient population. The FDA has set a target action date of February 23, 2027.

Arcutis Biotherapeutics has launched a new virtual health platform to expand access to its ZORYVE portfolio for chronic inflammatory skin diseases. The platform connects individuals with independent, board-certified dermatologists through a streamlined digital experience, targeting the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis. It is designed to complement traditional in-office care by offering a convenient alternative for those who have not seen a dermatologist or face barriers such as long wait times and geographic limitations. Participating dermatologists independently evaluate and prescribe treatment, with ZORYVE prescriptions coordinated through a national pharmacy hub for insurance support and home delivery. The launch reflects Arcutis' commitment to improving access to care beyond new treatments.

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics’ ZORYVE cream 0.3% for the topical treatment of plaque psoriasis in children as young as 2 years old. ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for this age group, and it is safe, effective, and well-tolerated for use anywhere on the body with no restrictions on duration of use. The approval is based on data from a maximal usage systemic exposure study and a long-term open-label extension study in children ages 2 to 5, which showed safety and efficacy consistent with pivotal Phase 3 trials in adolescents and adults. This marks the seventh FDA approval for ZORYVE in four years, expanding the previous indication that covered adults and children down to age 6. Arcutis states that ZORYVE cream is widely available through key wholesaler and dermatology pharmacy channels, with patient support programs to assist with access and affordability.

Arcutis Biotherapeutics director Sue-Jean Lin sold 4,946 shares of common stock for approximately $121,000 on June 15, 2026, according to an SEC filing. The transaction was executed under a 10b5-1 trading plan adopted in December 2025 and reduced her direct holdings by 15% to 27,567 shares. The sale occurred against a backdrop of strong commercial performance, with first-quarter net product revenue for the ZORYVE franchise climbing 65% year over year to $105.4 million. Arcutis posted a narrower quarterly loss of $11.3 million and maintained full-year revenue guidance of $480 million to $495 million.